These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23109404)

  • 1. Inhibitors in childhood hemophilia A: genetic and treatment-related risk factors for development and eradication.
    DiMichele DM
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S30-3. PubMed ID: 23109404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
    Gouw SC; van den Berg HM
    Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent improvements in the clinical treatment of coagulation factor inhibitors.
    Franchini M; Lippi G
    Semin Thromb Hemost; 2009 Nov; 35(8):806-13. PubMed ID: 20169517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors in mild/moderate haemophilia A: an update.
    Franchini M; Salvagno GL; Lippi G
    Thromb Haemost; 2006 Aug; 96(2):113-8. PubMed ID: 16894451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between factor VIII genotype and inhibitor development in hemophilia A.
    Fakharzadeh SS; Kazazian HH
    Semin Thromb Hemost; 2000; 26(2):167-71. PubMed ID: 10919409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of factor VIII after inhibitor clearance in patients with moderate haemophilia A: a case series.
    Tran DQ; Harvey RD; Meeks SL; Chapman R; Kempton CL
    Haemophilia; 2014 Jul; 20(4):e344-6. PubMed ID: 24750497
    [No Abstract]   [Full Text] [Related]  

  • 7. Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity.
    Matino D; Lillicrap D; Astermark J; Dolan G; Kessler C; Lambert T; Makris M; O'Donnell J; Pipe S; Santagostino E; Saint-Remy JM; Schramm W; Iorio A
    Haemophilia; 2014 Mar; 20(2):200-6. PubMed ID: 24533949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of inhibitors and current treatment strategies.
    Kreuz W; Ettingshausen CE; Auerswald G; Saguer IM; Becker S; Funk M; Heller C; Klarmann D; Klingebiel T;
    Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing risk factors: prevention of inhibitors in haemophilia.
    Chambost H
    Haemophilia; 2010 Mar; 16 Suppl 2():10-5. PubMed ID: 20132333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors.
    Gomperts ED
    Haemophilia; 2006 Nov; 12(6):573-8. PubMed ID: 17083506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of inhibitors.
    Astermark J
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
    Astermark J
    Haemophilia; 2006 Jul; 12 Suppl 3():52-60. PubMed ID: 16683997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
    Gouw SC; Van Der Bom JG; Van Den Berg HM; Zewald RA; Ploos Van Amstel JK; Mauser-Bunschoten EP
    Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitor development: patient-determined risk factors.
    Astermark J
    Haemophilia; 2010 May; 16(102):66-70. PubMed ID: 19298384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phage display technology: a tool to explore the diversity of inhibitors to blood coagulation factor VIII.
    Voorberg J; van den Brink EN
    Semin Thromb Hemost; 2000; 26(2):143-50. PubMed ID: 10919406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
    Kreuz W; Becker S; Lenz E; Martinez-Saguer I; Escuriola-Ettingshausen C; Funk M; Ehrenforth S; Auerswald G; Kornhuber B
    Semin Thromb Hemost; 1995; 21(4):382-9. PubMed ID: 8747701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors.
    Lozier JN; Santagostino E; Kasper CK; Teitel JM; Hay CR
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):10-21. PubMed ID: 8480192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of genetics in inhibitor formation.
    Gill JC
    Thromb Haemost; 1999 Aug; 82(2):500-4. PubMed ID: 10605742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.